Skip to main content

Table 4 Univariate analysis of the prognostic value of miR-125b-5p expression levels in relation to relapse-free survival in different hormone receptor–positive breast cancers a

From: MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer

  Number of samples Univariate analysis
Hazard ratio 95% CI P -value b
All breast tumor samples 65 6.80 1.35 to 35.26 0.009
HR+/HER2− subclass 30 4.81 N/A 0.03
Luminal A subclass (HR+, HER2−, SBR1 or SBR2)c 19 3.75 N/A 0.05
Luminal B subclass (HR+, HER2+ and/or SBR3)c 17 1.69 0.07 to 17.12 0.96
  1. a95% CI, 95% confidence interval; HER2, Human epidermal growth factor receptor 2; HR+, Hormone receptor–positive (estrogen receptor (ER) and/or progesterone receptor (PR)); miR, MicroRNA; N/A, Not applicable as there is no relapse event in the low miR-125b-5p expression level group; SBR, Scarff-Bloom-Richardson grade. b P < 0.05 was considered significant. cSubclasses of breast cancer were determined using immunohistological (ER, PR, HER2) and SBR grades according to the St Gallen recommendation [38].